Vorapaxar

(Zontivity®)

Vorapaxar

Drug updated on 11/13/2023

Dosage FormTablet (oral: 2.08 mg)
Drug ClassProtease-activated receptor-1 (PAR-1) antagonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD).